Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Schwaiger, M; Wallner, J; Zemann, W; Aichner, S; Zrnc, T; Metzler, P.
[Application of tranexamic acid within the field of dentistry].
Swiss Dent J. 2021; 131(10):827-829
PubMed
- Führende Autor*innen der Med Uni Graz
- Schwaiger Michael
- Co-Autor*innen der Med Uni Graz
- Metzler Philipp
- Wallner Jürgen
- Zemann Wolfgang
- Zrnc Tomislav
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Abstract:
- The antifibrinolytic agent tranexamic acid (TXA) is well known for its capacity to effectively reduce intraoperative blood loss. The effect mechanism of TXA is based on the indirect inhibition of fibrin degradation, whereby existing blood clots within the surgical area are stabilized. Consecutively, the amount of blood loss can be reduced. Due to its great efficacy to minimize blood loss and its low rate of unintended side effects, TXA is regularly used in different surgical fields. Within the field of dentistry TXA is not applied on a regular basis, however, it presents a highly effective and convenient treatment option to reduce bleeding complications.
- Find related publications in this database (using NLM MeSH Indexing)
- Antifibrinolytic Agents - therapeutic use
- Blood Loss, Surgical - prevention & control
- Dentistry - administration & dosage
- Humans - administration & dosage
- Tranexamic Acid - therapeutic use